GlassScriptPhysician profile
Angela Aiyan Lu
NPI 1336816123
$6,658.57
in general payments reported to CMS, 2019-2025
40 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $2,665 · 2023: $3,120 · 2024: $469 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,631.02 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $649.57 | 2022-2023 | Tagrisso, Imjudo |
| E.R. Squibb & Sons, L.L.C. | $436.63 | 2022-2023 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $420.26 | 2022-2025 | |
| Pfizer INC. | $418.66 | 2022-2024 | |
| Amgen INC. | $396.95 | 2022-2025 | Uplizna, Lumakras, Nplate |
| Janssen Biotech, INC. | $356.97 | 2022-2023 | Erleada, Darzalex, Imbruvica |
| Merck Sharp & Dohme LLC | $355.46 | 2022-2023 | Keytruda, Welireg, Lynparza |
| Beigene USA, INC. | $281.28 | 2022-2023 | Brukinsa |
| Incyte Corporation | $252.29 | 2022-2023 | Pemazyre, Monjuvi, Jakafi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.54 | 2021-2023 | Gilotrif |
| Eisai INC. | $205.57 | 2022-2023 | |
| Foundation Medicine, INC. | $178.28 | 2022-2023 | |
| Celgene Corporation | $168.75 | 2022-2023 | Opdualag, Pomalyst, Reblozyl |
| Seagen INC. | $164.35 | 2022-2023 | Tukysa, Adcetris, Padcev |
| Sobi, INC | $142.68 | 2022-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $140.84 | 2023 | Krazati |
| Regeneron Healthcare Solutions, INC. | $140.75 | 2022-2023 | Libtayo |
| Daiichi Sankyo INC. | $137.44 | 2022-2023 | Injectafer, Enhertu |
| Sirtex Medical INC | $134.48 | 2023 | Sir-Spheres Microspheres |
| Bayer Healthcare Pharmaceuticals INC. | $134.11 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.61 | 2022-2023 | Ninlaro, Alunbrig, Iclusig |
| Emd Serono, INC. | $130.56 | 2022-2023 | Tepmetko, Bavencio |
| Gilead Sciences, INC. | $126.08 | 2022-2023 | Trodelvy |
| Genzyme Corporation | $108.00 | 2022-2023 | |
| Astellas Pharma US INC | $95.99 | 2022-2024 | Xtandi |
| Myovant Sciences INC. | $94.03 | 2022 | |
| Abbvie INC. | $83.59 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $79.00 | 2024 | |
| Taiho Oncology, INC. | $69.28 | 2022-2023 | |
| Adaptive Biotechnologies Corporation | $64.53 | 2022-2023 | Clonoseq |
| Rigel Pharmaceuticals, INC. | $50.55 | 2023 | Tavalisse, Rezlidhia |
| Kyowa Kirin, INC. | $48.14 | 2022 | |
| Lilly USA, LLC | $46.98 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $45.41 | 2023 | Orgovyx |
| Genmab U.S., INC. | $26.09 | 2023 | Epkinly |
| Array Biopharma INC | $24.90 | 2022 | |
| Stemline Therapeutics INC. | $23.34 | 2023 | Orserdu |
| Aadi Bioscience, INC. | $22.92 | 2025 | Fyarro |
| Alexion Pharmaceuticals, INC. | $22.72 | 2023 | Ultomiris |
| Glaxosmithkline, LLC. | $19.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.